Integrated bioinformatics analysis for the identification of potential key genes affecting the pathogenesis of clear cell renal cell carcinoma

Hao Cui(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Xiaofang Che(First Hospital of China Medical University), Lei Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Kezuo Hou(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Bofang Liu(First Hospital of China Medical University)
Oncology Letters
June 5, 2020
10.3892/ol.2020.11703
Cited by 13

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437